UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

6ER-009 Comparative efficacy of abemaciclib and palbociclib as adjuvant treatment in patients with early breast cancer

European journal of hospital pharmacy. Science and practice, 2023-03, Vol.30 (Suppl 1), p.A162-A163

2023

Volltextzugriff (PDF)

4CPS-166 Association between immune-related effects and effectiveness of first-line pembrolizumab in advanced non-small-cell lung cancer

European journal of hospital pharmacy. Science and practice, 2022-03, Vol.29 (Suppl 1), p.A84-A85

2022

Volltextzugriff (PDF)

2SPD-009 Analysis of olaparib and talazoparib as possible therapeutic alternatives in advanced breast cancer and a germline BRCA mutation

European journal of hospital pharmacy. Science and practice, 2019-03, Vol.26 (Suppl 1), p.A23-A23

2019

Volltextzugriff (PDF)

Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis

Journal of clinical pharmacy and therapeutics, 2013-08, Vol.38 (4), p.286-293

2013

Volltextzugriff (PDF)

Evaluación de los comparadores empleados en los estudios pivotales de nuevos medicamentos e indicaciones

Revista de la OFIL, 2023-09, Vol.33 (3), p.221-235

2023

Volltextzugriff (PDF)

4CPS-150 Use of adalimumab for hidradenitis suppurativa

European journal of hospital pharmacy. Science and practice, 2018-03, Vol.25 (Suppl 1), p.A112-A112

2018

Volltextzugriff (PDF)

4CPS-161 Determination of drug serum levels to optimise treatment of patients with psoriasis

European journal of hospital pharmacy. Science and practice, 2018-03, Vol.25 (Suppl 1), p.A117-A117

2018

Volltextzugriff (PDF)

1ISG-009 Economic impact of aflibercept optimisation for the treatment of eye-related conditions

European journal of hospital pharmacy. Science and practice, 2018-03, Vol.25 (Suppl 1), p.A4-A4

2018

Volltextzugriff (PDF)

Incorporar la evidencia en tiempos del COVID-19

Revista de la OFIL, 2020, Vol.30 (2), p.91-92

Alegre del Rey, EJ

2020

Volltextzugriff (PDF)

CP-140 Analysis of distribution and acceptability of pharmaceutical interventions after implantation of the electronic assisted prescription

European journal of hospital pharmacy. Science and practice, 2017-03, Vol.24 (Suppl 1), p.A63-A63

2017

Volltextzugriff (PDF)

Coste-efectividad del evolocumab. Respuesta

Revista española de cardiologia, 2018-12, Vol.71 (12), p.1090-1090

2018

Volltextzugriff (PDF)

DI-063 Survival benefit with vemurafenib in ‘braf’ mutation positive melanoma: Area under the curve based reanalysis

European journal of hospital pharmacy. Science and practice, 2016-03, Vol.23 (Suppl 1), p.A146-A146

2016

Volltextzugriff (PDF)

OHP-036 Ajusted indirect comparison of intravitreal aflibercept versus intravitreal bevacizumab in wet-age related macular degeneration

European journal of hospital pharmacy. Science and practice, 2014-03, Vol.21 (Suppl 1), p.A200-A200

2014

Volltextzugriff (PDF)

2SPD-006 Are all biologic agents in the treatment of ankylosing spondylitis equivalent alternatives?

European journal of hospital pharmacy. Science and practice, 2023-03, Vol.30 (Suppl 1), p.A8-A9

2023

Volltextzugriff (PDF)

Expresiones y criterios mejorables en la redacción de informes de evaluación y posicionamiento terapéutico

Revista de la OFIL, 2021, Vol.31 (2), p.219-223

2021

Volltextzugriff (PDF)

Píldora poscoital: un debate científico necesario

Gaceta sanitaria, 2016-09, Vol.30 (5), p.401-402

2016

Volltextzugriff (PDF)

1ISG-004 Economic comparison of therapeutic alternatives for firstline treatment of multiple myeloma

European journal of hospital pharmacy. Science and practice, 2020-03, Vol.27 (Suppl 1), p.A2-A2

2020

Volltextzugriff (PDF)

Evaluación y posicionamiento de medicamentos como alternativas terapéuticas equivalentes

Medicina clínica, 2014-07, Vol.143 (2), p.85-90

2014

Volltextzugriff (PDF)

CPC-023 Assessment of the Whole Interceptive and Post-Fertilisation Effects of Postcoital Levonorgestrel

European journal of hospital pharmacy. Science and practice, 2013-03, Vol.20 (Suppl 1), p.A173-A174

2013

Volltextzugriff (PDF)

4CPS-076 Indirect comparison between pembrolizumab monotherapy and pembrolizumab chemotherapy regimens in squamous lung cancer

European journal of hospital pharmacy. Science and practice, 2020-03, Vol.27 (Suppl 1), p.A82-A83

2020

Volltextzugriff (PDF)

4CPS-132 Indirect treatment comparison of anti-calcitonin gene related peptide pathway antibodies in chronic migraine

European journal of hospital pharmacy. Science and practice, 2020-03, Vol.27 (Suppl 1), p.A109-A110

2020

Volltextzugriff (PDF)

2SPD-033 Evaluation of docetaxel in low and high burden metastatic hormone sensitive prostate cancer

European journal of hospital pharmacy. Science and practice, 2021-03, Vol.28 (Suppl 1), p.A8-A8

2021

Volltextzugriff (PDF)

2SPD-034 Use of daratumumab based treatments in patients with multiple myeloma and hepatic impairment

European journal of hospital pharmacy. Science and practice, 2021-03, Vol.28 (Suppl 1), p.A8-A9

2021

Volltextzugriff (PDF)

2SPD-032 Network meta-analysis of therapeutic alternatives in untreated metastatic squamous non-small cell lung cancer

European journal of hospital pharmacy. Science and practice, 2021-03, Vol.28 (Suppl 1), p.A7-A8

2021

Volltextzugriff (PDF)

1ISG-021 Indirect comparison of brigatinib versus alectinib in ALK positive non-small cell lung cancer

European journal of hospital pharmacy. Science and practice, 2021-03, Vol.28 (Suppl 1), p.A1-A2

2021

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(40)

Sprache

Erscheinungsjahr

n.n

Thema

Monoclonal Antibodies
(10)
Conflicts Of Interest
(9)
Immunotherapy
(8)
Targeted Cancer Therapy
(7)
Lung Cancer
(6)
Patients
(5)
Metastasis
(4)
Pharmacology & Pharmacy
(4)
Clinical Trials
(3)
Psoriasis
(3)
Section 4: Clinical Pharmacy Services
(3)
Breast Cancer
(2)
Cancer Therapies
(2)
Coronaviruses
(2)
Covid-19
(2)
Hepatitis
(2)
Hepatitis C
(2)
Humans
(2)
Infections
(2)
Internal Medicine
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

6ER-009 Comparative efficacy of abemaciclib and palbociclib as adjuvant treatment in patients with early breast cancer

4CPS-166 Association between immune-related effects and effectiveness of first-line pembrolizumab in advanced non-small-cell lung cancer

2SPD-009 Analysis of olaparib and talazoparib as possible therapeutic alternatives in advanced breast cancer and a germline BRCA mutation

Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis

Evaluación de los comparadores empleados en los estudios pivotales de nuevos medicamentos e indicaciones

4CPS-150 Use of adalimumab for hidradenitis suppurativa

4CPS-161 Determination of drug serum levels to optimise treatment of patients with psoriasis

1ISG-009 Economic impact of aflibercept optimisation for the treatment of eye-related conditions

Incorporar la evidencia en tiempos del COVID-19

CP-140 Analysis of distribution and acceptability of pharmaceutical interventions after implantation of the electronic assisted prescription

Coste-efectividad del evolocumab. Respuesta

DI-063 Survival benefit with vemurafenib in ‘braf’ mutation positive melanoma: Area under the curve based reanalysis

OHP-036 Ajusted indirect comparison of intravitreal aflibercept versus intravitreal bevacizumab in wet-age related macular degeneration

2SPD-006 Are all biologic agents in the treatment of ankylosing spondylitis equivalent alternatives?

Expresiones y criterios mejorables en la redacción de informes de evaluación y posicionamiento terapéutico

Píldora poscoital: un debate científico necesario

1ISG-004 Economic comparison of therapeutic alternatives for firstline treatment of multiple myeloma

Evaluación y posicionamiento de medicamentos como alternativas terapéuticas equivalentes

CPC-023 Assessment of the Whole Interceptive and Post-Fertilisation Effects of Postcoital Levonorgestrel

4CPS-076 Indirect comparison between pembrolizumab monotherapy and pembrolizumab chemotherapy regimens in squamous lung cancer

4CPS-132 Indirect treatment comparison of anti-calcitonin gene related peptide pathway antibodies in chronic migraine

2SPD-033 Evaluation of docetaxel in low and high burden metastatic hormone sensitive prostate cancer

2SPD-034 Use of daratumumab based treatments in patients with multiple myeloma and hepatic impairment

2SPD-032 Network meta-analysis of therapeutic alternatives in untreated metastatic squamous non-small cell lung cancer

1ISG-021 Indirect comparison of brigatinib versus alectinib in ALK positive non-small cell lung cancer

Suchergebnisse filtern